The PEARL-SIMPLIFIED trial is a multicenter, prospective, randomized controlled, open-label, blinded-endpoint study. It aims to evaluate the efficacy and safety of intravenous tenecteplase (TNK) in patients with acute ischemic stroke (AIS) presenting in the extended 4.5-24 hour window, using a simplified imaging selection strategy based solely on non-contrast CT (NCCT).
The PEARL-SIMPLIFIED trial is a multicenter, prospective, randomized controlled, open-label, blinded-endpoint study with a target enrollment of at least 750 patients. The trial focuses on individuals with acute ischemic stroke (AIS) presenting within a 4.5 to 24-hour window who are not planned for endovascular thrombectomy (EVT). Patients meeting simplified imaging criteria based on non-contrast CT (NCCT) are randomized 1:1 to receive a single intravenous bolus of 0.25 mg/kg tenecteplase (TNK) or standard medical treatment. The primary outcome is the 90-day excellent functional outcome, defined as a modified Rankin Scale (mRS) score of 0-1. Safety outcomes include symptomatic intracranial hemorrhage (sICH) and 90-day mortality.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
750
Patients randomized to the intervention arm will receive tenecteplase via a single intravenous bolus (0.25 mg/kg; maximum dose 25 mg), administered immediately following randomization.
Patients in the control arm will receive standard medical treatment.
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, China
Excellent functional outcome
The proportion of mRS score 0-1 at 90 (±14) days.
Time frame: at 90 (±14) days
Ordinal distribution of mRS
The proportion of mRS distribution at 90 (±14) days
Time frame: at 90 (±14) days
Favorable functional outcome
The proportion of mRS score 0-2 at 90 (±14) days
Time frame: at 90 (±14) days
Change in NIHSS Score at 24 (±12) hours
NIHSS score change from baseline at 24 (±12) hours
Time frame: at 24 (±12) hours
Change in NIHSS Score at 7 (±1) days or discharge
NIHSS score change from baseline at 7 (±1) days or discharge
Time frame: at 7 (±1) days or discharge
Quality of life (EQ-5D-5L)
Quality of life measured by EQ-5D-5L at 90 (±14) days
Time frame: at 90 (±14) days
Symptomatic intracranial hemorrhage
Symptomatic intracranial hemorrhage (sICH) within 36 hours from randomization (SITS-MOST criteria)
Time frame: within 36 hours
Any intracranial hemorrhage
Any intracranial hemorrhage within 36 hours
Time frame: within 36 hours
Major extracranial bleeding
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Major extracranial bleeding within 36 hours (GUSTO criteria: moderate and severe bleeding)
Time frame: within 36 hours
Mortality
All-cause mortality within 90 days
Time frame: within 90 days